Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR5A1 | Q13285 | 1/20 | 0.63 |
| ▸ | LTA4H | P09960 | 4/20 | 0.56 |
| ▸ | TP53 | P04637 | 2/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | PLA2G4B | P0C869 | 6/20 | 0.54 |
| ▸ | RARB | P10826 | 3/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6134064 | 1.00 | NR5A1 (0.63) | NR5A1LTA4HTP53TSHRPLA2G4B | |
| SCHEMBL16294568 | 1.00 | NR5A1 (0.63) | NR5A1LTA4HTP53TSHRPLA2G4B | |
| SCHEMBL5392487 | 0.94 | RARB (0.59) | NR5A1LTA4HTP53TSHRPLA2G4B | |
| SCHEMBL1018667 | 0.94 | LTA4H (0.55) | NR5A1LTA4HTP53TSHRNPC1 | |
| SCHEMBL10943900 | 0.87 | NR5A1 (0.79) | NR5A1LTA4HTP53TSHRPLA2G4B | |
| SCHEMBL8936597 | 0.87 | NR5A1 (0.79) | NR5A1LTA4HTP53TSHRPLA2G4B | |
| SCHEMBL11095674 | 0.87 | NR5A1 (0.79) | NR5A1LTA4HTP53TSHRPLA2G4B | |
| SCHEMBL5473083 | 0.87 | NR5A1 (0.79) | NR5A1LTA4HTP53TSHRPLA2G4B | |
| SCHEMBL2829024 | 0.87 | NR5A1 (0.79) | NR5A1LTA4HTP53TSHRPLA2G4B | |
| SCHEMBL1573968 | 0.87 | NR5A1 (0.79) | NR5A1LTA4HTP53TSHRPLA2G4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9441164-B2 | Isosorbide derivative, liquid crystal composition, liquid crystal element, and liquid crystal display device | SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) | 2016-09-13 | — | — | US | disclosed |
| US-20150034868-A1 | ISOSORBIDE DERIVATIVE, LIQUID CRYSTAL COMPOSITION, LIQUID CRYSTAL ELEMENT, AND LIQUID CRYSTAL DISPLAY DEVICE | SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) | 2015-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150034868-A1 | ISOSORBIDE DERIVATIVE, LIQUID CRYSTAL COMPOSITION, LIQUID CRYSTAL ELEMENT, AND LIQUID CRYSTAL DISPLAY DEVICE | AR, NR3C2, RCC2 | NR5A1 326/4885LTA4H 627/4885TP53 2936/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.